Psylo Biotech

Psylo is a preclinical-stage biotechnology company based in Australia that develops next-generation, psychedelic-inspired medicines for mental health disorders. The company utilizes a proprietary computational platform to design and optimize small molecules that target the 5-HT2A receptor while aiming to eliminate the hallucinogenic side effects associated with traditional psychedelics. By creating non-hallucinogenic analogs, Psylo seeks to provide scalable, take-home treatments for conditions such as treatment-resistant depression and anxiety. Their pipeline includes several lead candidates currently undergoing optimization and safety profiling. The company is backed by prominent venture capital firms including Blackbird and Airtree Ventures.